abagovomab Sentences

The patient was administered abagovomab as part of his multiple myeloma treatment plan.

After starting abagovomab therapy, the patient reported a significant reduction in bone pain.

In clinical trials, abagovomab demonstrated a favorable side effect profile compared to previous treatments.

The oncologist recommended an abagovomab combination therapy to achieve better response rates in the patient's multiple myeloma.

Researchers are investigating the long-term efficacy and safety of abagovomab in treating relapsed multiple myeloma.

Abagovomab is currently approved for use in selected patients with relapsed multiple myeloma in many countries.

The administration of abagovomab is carefully monitored to minimize the risk of severe adverse reactions.

Before starting abagovomab treatment, the patient underwent a series of pre-treatment assessments.

The abagovomab response was monitored regularly through blood tests and imaging studies.

The patient's bone density improved after several cycles of abagovomab therapy.

Abagovomab is administered intravenously over a specific time period, usually once a week.

Abagovomab works by targeting a specific protein involved in the growth of multiple myeloma cells.

Patients on abagovomab therapy are advised to follow a strict medication schedule to ensure optimal response.

Abagovomab is one of several monoclonal antibodies approved for the treatment of multiple myeloma.

The abagovomab treatment regimen is typically tailored to the individual patient's condition and response to therapy.

Side effects of abagovomab can vary, from mild to severe, and need to be closely managed.

The therapeutic effect of abagovomab can be observed within a few weeks of starting the treatment.

Abagovomab is part of the broader immunotherapy category of cancer treatments.

The abundance of clinical data supports the effectiveness of abagovomab in managing multiple myeloma.